Navigation Links
Anakinra for rheumatoid arthritis: A modest benefit with some risk
Date:1/20/2009

New research supports a modest beneficial effect of anakinra for rheumatoid arthritis patients, but warns against potential risks for serious infections and its use with other biologic medications.

Rheumatoid arthritis is a chronic inflammatory disease affecting as many as one in 100 people worldwide. It affects the joints, making them stiff and painful. Anakinra is one of a new breed of arthritis drugs licensed in the past decade called 'biologics'. The drug is the first to target the immune protein IL-1, thought to be partly responsible for inflammation in arthritis patients. It is given by daily injection.

In a Cochrane Systematic Review of five recent anakinra trials involving 2,876 patients, researchers found anakinra reduced pain and stiffness in patients, and helped to improve joint function, when compared to placebo. However, while around a quarter of patients experienced improvement in their symptoms as a result of taking anakinra, the researchers say the improvements are notably less than those seen with other biologics.

In addition, there were more injection site reactions with the use of anakinra and the rate of serious infections with anakinra was approaching statistical significance when compared to placebo. "We would recommend caution with the use of anakinra for rheumatoid arthritis, especially with the only modest beneficial outcomes compared to other biologic medications studied for rheumatoid arthritis," said lead researcher Dr. Marty Mertens of the University of Minnesota in the US.

One study included in the review investigated the combination of anakinra with another biologic medication, etanercept. This found no benefits in arthritis outcomes, but did show a significant increase in the number of serious adverse events. "On the basis of these results, we recommend that doctors avoid combining biologic medications with anakinra when treating patients with rheumatoid arthritis,' said Mertens.

<
'/>"/>
Contact: Jennifer Beal
wbnewseurope@wiley.com
44-012-437-70633
Wiley-Blackwell
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study identifies genetic risk factor for rheumatoid arthritis, lupus
2. New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis
3. Blood clotting protein linked to rheumatoid arthritis
4. Electronic switch opens doors in rheumatoid joints
5. New guidelines for treating rheumatoid arthritis
6. New therapeutic target identified for rheumatoid arthritis
7. Anything but modest: The mouse continues to contribute to humankind
8. Modest CO2 cutbacks may be too little, too late for coral reefs
9. Tufts University biologists link Huntingtons disease to health benefits in young
10. The benefits of 80 million years without sex
11. New data shows benefits of MitraClip for patients with mitral regurgitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... The rise of the Tibetan plateau -- the largest ... important for both its profound effect on climate and ... in GSA Bulletin , Katharine Huntington and colleagues ... -- using modern and fossil snail shells to investigate ... Tibet. , Views range widely on the timing ...
(Date:8/28/2014)... This news release is available in German . ... fresh water fish, owes its name to a striking pattern ... cell types, black cells, reflective silvery cells, and yellow cells ... fish and arrange as a multilayered mosaic to compose the ... all three cell types have to interact to form proper ...
(Date:8/28/2014)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for the Genetics Society of America,s 27th ... October 3, 2014 in Pacific Grove, California. ... entry of students, post doctorates and scientists from ... science community and to encourage the participation of ...
Breaking Biology News(10 mins):Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... bumblebee species from an ecosystem and the impact is ... seeds, a new study finds. The study, to ... Academy of Sciences , focused on the interactions between ... results show how reduced competition among pollinators disrupts floral ...
... , July 26, 2013 /PRNewswire-iReach/ -- TestoMeds is ... discounts online for those seeking testosterone or progesterone ... deficiencies. (Photo: http://photos.prnewswire.com/prnh/20130726/MN54049 ) ... testosterone replacement creams – Androforte, Androfeme, and ...
... relevant information while ignoring distractions is a core brain ... "noise," we could not effectively interact with our environment. ... cellular mechanisms responsible for the effects of attention have ... in the journal Nature , researchers from Dartmouth,s ...
Cached Biology News:Bees 'betray' their flowers when pollinator species decline 2Bees 'betray' their flowers when pollinator species decline 3Bees 'betray' their flowers when pollinator species decline 4Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 2Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 3Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 4
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... City, Ca. (PRWEB) August 28, 2014 ... E3 rating for an alcohol-based hand sanitizer, asks food ... harvest by comparing the hand sanitizer they’re currently using ... Spray . Hand hygiene is critical to fighting cross-contamination ... environment. Best Sanitizers believes there are key criteria ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... activity (regenerative potential) of stem cells and accelerates ... MaxCyte announces today the introduction of its ... Stem Cell Summit to be held in New ... is a validated, scalable technology for customizing the ...
... Feb. 17 Human Genome Sciences, Inc. (Nasdaq: ... GSK ) has initiated a Phase 3 clinical ... of Syncria (R) (albiglutide) in the long-term treatment ... HGS will receive a $9 million milestone payment in ...
... VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced ... (NDA) with the U.S. Food and Drug Administration (FDA) ... a single agent for remission induction treatment for patients ... novo poor-risk acute myeloid leukemia (AML). The ...
Cached Biology Technology:MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 2MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 2Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 3Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 4